Acromegaly screening: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
According to the endocrine society, screening for acromegaly is recommended among patients with clinical features of acromegaly. These features include enlarged [[hands]] and [[feet]], [[frontal]] protrusion, and [[skin]] thickening. The screening is performed by measurement of the [[IGF-1]]. | |||
== Screening == | == Screening == | ||
*According to the endocrine society, screening for acromegaly by measurement of IGF-1 is recommended among patients with the clinical features of acromegaly. These features include the following:<ref name="pmid25356808">{{cite journal| author=Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A et al.| title=Acromegaly: an endocrine society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 11 | pages= 3933-51 | pmid=25356808 | doi=10.1210/jc.2014-2700 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25356808 }} </ref> | *According to the endocrine society, screening for acromegaly by measurement of IGF-1 is recommended among patients with the clinical features of acromegaly. These features include the following:<ref name="pmid25356808">{{cite journal| author=Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A et al.| title=Acromegaly: an endocrine society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 11 | pages= 3933-51 | pmid=25356808 | doi=10.1210/jc.2014-2700 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25356808 }} </ref> | ||
**Enlarged hands and feet | **Enlarged [[hands]] and [[feet]] | ||
**Change in the facial features | **Change in the [[facial]] features | ||
**Headache | **[[Headache]] | ||
**Increase sweating | **Increase [[sweating]] | ||
**Paraesthesia | **[[Paraesthesia]] | ||
**Skin thickening | **[[Skin]] thickening | ||
**Protrusion of the lower jaw | **Protrusion of the lower [[jaw]] | ||
*Screening also is recommended in patients with associated conditions of acromegaly. Acromegaly is associated with different comorbidities so that screening is important in patients with these comorbidities which include: | *Screening also is recommended in patients with associated conditions of acromegaly. Acromegaly is associated with different comorbidities so that screening is important in patients with these comorbidities which include: | ||
**Diabetes Mellitus | **[[Diabetes mellitus|Diabetes Mellitus]] | ||
**Carpal tunnel syndrome | **[[Carpal tunnel syndrome]] | ||
**Arthritis | **[[Arthritis]] | ||
**Sleep apnea | **[[Sleep apnea]] | ||
**Hypertension | **[[Hypertension]] | ||
==References== | ==References== | ||
Revision as of 16:57, 14 August 2017
|
Acromegaly Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acromegaly screening On the Web |
|
American Roentgen Ray Society Images of Acromegaly screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
According to the endocrine society, screening for acromegaly is recommended among patients with clinical features of acromegaly. These features include enlarged hands and feet, frontal protrusion, and skin thickening. The screening is performed by measurement of the IGF-1.
Screening
- According to the endocrine society, screening for acromegaly by measurement of IGF-1 is recommended among patients with the clinical features of acromegaly. These features include the following:[1]
- Screening also is recommended in patients with associated conditions of acromegaly. Acromegaly is associated with different comorbidities so that screening is important in patients with these comorbidities which include:
References
- ↑ Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A; et al. (2014). "Acromegaly: an endocrine society clinical practice guideline". J Clin Endocrinol Metab. 99 (11): 3933–51. doi:10.1210/jc.2014-2700. PMID 25356808.